Cynata: eveything in place for a big run, page-22

Yes I was one of them. Frustrated with the seeming lack of support for retailers from the BoD, bourne out of fear that we might head into the latter part of 2018 needing a CR. But then out of nowhere came the extremely successful cohort A result, which surprised me and everyone else with positive efficacy readings as well as 100% safety in the group. Then suddenly the clinical peers started paying attention and new relationships started appearing, then some really interesting action in the market suggesting that a whale has appeared on the register. And finally, a surge of deals in the general pharma development world where juniors with less disruptive technology than Cynata are getting paid big, big dollars.